Attention for medical specialists: PJSC "Kraspharma" registered a new drug - Fluoroquinolone IV generation Moxifloxacin solution for infusions 1.6 mg / ml.

PJSC "Krasfarma" expands its product portfolio - the new antimicrobial drug from the group of fluoroquinolones Moxifloxacin in the dosage form "solution for infusions" of 1.6 mg/ml was registered.

Moxifloxacin – fluoroquinolone IV generation with a wide range of activities, including the most important gram (+) and gram ( -) bacteria, as well as anaerobes, atypical pathogens and mycobacteria. An important feature of the activity spectrum of the drug Moxifloxacin is its action against microorganisms resistant to cephalosporins and macrolides.

Moxifloxacin in has a wide range of indications for use, first of all - lower respiratory tract infections, intraabdominal infections and complicated skin and soft tissue infections.

When using Moxifloxacin in mixed aerobic-anaerobic infections, its combination with anti-anaerobic drugs is unnecessary.
Moxifloxacin is characterized by good tolerability of therapy and a high safety profile.

Detailed description of the drug Moxifloxacin is available at the link >>.

Back to news list